ABPI names new president
pharmafile | December 10, 2007 | News story | |Â Â ABPIÂ
AstraZeneca's Chris Brinsmead has been named as the next president of the ABPI.
He will take over from the current ABPI president, Sanofi-Aventis UK's managing director Nigel Brooksby, in April next year.
Mr Brinsmead said: "In taking over the reins from Nigel Brooksby, I will continue to seek to ensure that patients have access to the appropriate medicines, that industry works in a way which meets the needs of professionals in the NHS, and that we can continue to focus on finding cures for the many unsolved medical needs at a cost which healthcare systems can afford."
The ABPI changes its presidency every two years, rotating the role among its board members. Brinsmead, who is president of AstraZeneca UK, sits on the ABPI's Governance Board and has been a member of the its Board of Management since 2002.
The ABPI president as well as its director general, currently Richard Barker, have an active role within the Ministerial Industry Strategy Group (MISG), a high-level group that brings together government and pharmaceutical industry representatives.
Mr Brinsmead commented: "The UK pharmaceutical industry has an excellent record of working with the UK Government. This relationship has always been focused on ensuring that patients get the best treatment and that this represents good value for the NHS.
"At a time of considerable change for the NHS and also for industry we must make sure that we strengthen this partnership."
The ABPI could face tough times next year, depending on whether government observe proposals from the OFT to scrap the current medicines pricing scheme (PPRS) in favour of Value-based pricing.
But ABPI leaders said earlier this year they were not worried about any surprises on this front, and seemed confident the PPRS, or some variation of it, will remain safe.
Mr Brinsmead graduated with a degree in Engineering and has over twenty years experience in the pharmaceutical industry, formerly with ICI and Zeneca, before taking on global responsibility at AstraZeneca for its oncology brand portfolio. He became AstraZeneca UK's company president in January 2002.
Related Content
The November 2020 issue of Pharmafocus is available to read free online now!
The latest monthly edition of Pharmafocus is available to read for free online now!
UK life sciences industry does not want no-deal Brexit, says ABPI Chief
Prime Minister Boris Johnson’s sudden change of position that the UK is now expecting a …
ABPI Chief Executive Mike Thompson to retire by the end of 2019
The Association of the British Pharmaceutical Industry (ABPI) has announced that its Chief Executive Mike …
